WASHINGTON, DC — A new Deloitte Center for Health Solutions report has shown that payors reimbursing for genetic tests to guide treatment see a "marginal" return on their investment.

The study, called "The ROI for Targeted Therapies: A Strategic Perspective Assessing the Barriers and Incentives for Adopting Personalized Medicine," showed that "all stakeholder groups experience a positive ROI under certain conditions, although payors received only a marginal benefit and that is after six years."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.